Navigation Links
Northwest Biotherapeutics Announces Registered Direct Offering
Date:8/9/2013

BETHESDA, Md., Aug. 9, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on August 8, 2013, it entered into an agreement with institutional investors, including an existing healthcare focused institutional investor and a dedicated healthcare mutual fund for a registered direct placement of $15 million of common stock at the price of $3.35 per share plus an additional over-allotment warrant, exercisable within 12 months, to sell an additional $3.75 million of common stock at the same price which, if exercised, would result in gross proceeds to the Company of $18.75 million.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

In addition, the Company will issue to each investor 25% warrant coverage to purchase shares of common stock with an exercise price of $4.00 per share.  These warrants are exercisable beginning six months after closing, with an exercise period of five years.

"We are very pleased to receive this financing from both new and existing top institutional investors specializing in healthcare," commented Linda Powers, CEO of NW Bio.  "This financing will provide substantial runway for the Company's multiple clinical programs."

The placement is expected to close on or before August 14, 2013, subject to satisfaction of customary closing conditions.

Oppenheimer & Co. Inc. acted as the lead placement agent for the transaction, and Summer Street Research Partners acted as the co-placement agent.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-185898), which was declared effective by t
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
2. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
3. HealthWarehouse.com and Northwest Physicians Network Partner to Provide Exclusive Discount Pharmacy Services to Patients
4. Northwest Bio Awarded $5.5 Million German Government Grant
5. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
6. iBio And Caliber Biotherapeutics Establish License And Collaboration Relationship
7. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
8. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
9. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. PDL BioPharma Announces Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Novagali Pharma, an,emerging pharmaceutical company specialized in ophthalmology,presents ... trial,positive results from the Phase III clinical study ... at the,XIV Afro-Asian Congress of ophthalmology (AACO) held ... , VKC is a severe form of chronic ...
... Interim results in a randomized phase II/III ... 26, 2007 /PRNewswire-FirstCall/ -- Cell,Therapeutics, Inc. (CTI) ... that treatment with pixantrone (BBR,2778) resulted in ... mitoxantrone induced significant cardiac damage.,The studies compared ...
Cached Medicine Technology:Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... of Medicine (BUSM) have discovered that the anti-seizure ... model. The findings, reported in the American ... lead to more effective treatments for alcoholism. , ... leading causes of illness and death in the ... limiting the productivity of workers and necessitating huge ...
(Date:4/17/2014)... A. Arias, M.D., Ph.D., at The University of Texas ... new superbug that caused a bloodstream infection in a ... issue of The New England Journal of Medicine ... class of highly-resistant bacteria known as methicillin-resistant Staphylococcus ... of hospital and community-associated infections. The superbug has also ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:New MRSA superbug emerges in Brazil 2
... may not be any more effective than giving them ... study.// ,Researchers studied 100 children with upper ... a common ingredient found in over-the-counter cough medicines. Another ... 34 children were given a placebo. ,Results of ...
... that’s responsible for controlling the activated leukocyte cell adhesion molecule ... cells stay clumped together. The gene is less active in ... don’t result in a spreading of the disease. Researchers speculate ... to more easily separate and migrate to other areas of ...
... the immune system may play a key role in women ... percent of all conceptions // fail, and around 1 percent ... many of the cases are due to fetal abnormalities, others ... research links the reproductive hormone secretion system to the immune ...
... SARS vaccine may be on the horizon. Researchers from ... a study involving eight African green monkeys. Four of ... using an intranasal vaccine made from a parainfluenza vaccine ... express a major antigen of the coronavirus that causes ...
... is a drop in blood pressure, say researchers, according ... on the association between blood pressure and Alzheimer’s disease ... on blood pressure variations before and after a diagnosis ... who were 75 or older. The participants had no ...
... down the progression of HIV, according to new research. Researchers ... progression of this deadly disease. Past studies have indicated that ... HIV. However researchers recently conducted a study to determine if ... included 1,078 pregnant women who were infected with HIV. The ...
Cached Medicine News:
... Recently updated with a high resolution ... new Kowa Non Myd - digital ... style and ease of use. Now ... easy to install VK-2 image and ...
... 2000 incorporates a full ... programs in precisely evaluating ... is a full-function, state-of-art ... efficient acquisition, storage, retrieval ...
Nidek LM-990A accomplishes precise measurement, quick response and easy operation....
Autolensmeter with black/white monitor and no internal printer....
Medicine Products: